01—Abstract
Summary
Summary of the 8-K filed July 10, 2024. Cited figures are marked; the original filing is the authoritative source.
Eli Lilly and Company (LLY) has announced a change in its Chief Financial Officer (CFO) role.
Anat Ashkenazi will be stepping down from her position as executive vice president and CFO to pursue opportunities outside the pharmaceutical industry. She will remain with the company until the end of July 2024 to ensure a smooth handover of her duties. Taking over as interim CFO, effective July 15, 2024, will be Gordon Brooks.
Mr. Brooks brings extensive experience to the role, having been with Eli Lilly for 29 years and holding various senior finance positions. This includes his recent role as group vice president, controller, and corporate strategy, as well as prior leadership positions in financial planning, procurement, and internal audit. The company has stated there are no specific arrangements or understandings related to his selection, no family ties to current executives, and no related-party transactions.
02—Key points
Key Highlights
- Anat Ashkenazi resigns as Executive Vice President and Chief Financial Officer, effective July 15, 2024.
- Gordon Brooks appointed as interim Chief Financial Officer, starting July 15, 2024.
- Mr. Brooks possesses 29 years of experience within Eli Lilly's finance organization.
- Ms. Ashkenazi will stay with the company through the end of July 2024 to aid in the transition.
- Mr. Brooks has held numerous senior finance leadership roles, including group vice president, controller, and corporate strategy.
- No specific arrangements or understandings, family relationships, or Item 404(a) transactions are noted concerning Mr. Brooks' appointment.
03—Questions
Frequently Asked Questions
Why is the current CFO, Anat Ashkenazi, leaving?
Anat Ashkenazi is leaving Eli Lilly to pursue a career opportunity outside of the pharmaceutical industry.
Who will replace Anat Ashkenazi as CFO?
Gordon Brooks will assume the role of interim Chief Financial Officer, effective July 15, 2024.
What is Gordon Brooks' experience at Eli Lilly?
Gordon Brooks has 29 years of experience with Eli Lilly and has held various senior finance leadership roles, including group vice president, controller, and corporate strategy. His prior experience also includes leadership in procurement, finance for specific business units, and internal audit.
Will Anat Ashkenazi be involved in the transition period?
Yes, Ms. Ashkenazi will remain with the Company through the end of July 2024 to facilitate the transition of her responsibilities.
04—Continue